Rigel Pharmaceuticals RIGL AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at other companies

Nuvation BioNUVB

——

Ionis PharmaceuticalsIONS

——

Other financials

Income statement

See full

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Balance sheet

See full

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Cash flow

See full

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Valuation

See full

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Profitability

See full

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Returns & leverage

See full

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's afs and trading securities - unrealized loss position (<12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rigel Pharmaceuticals's AFS and trading securities - unrealized loss position (<12 months) fair value?: Rigel Pharmaceuticals (RIGL) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $95.28M in Q1 2026.